# Case Report: Remarkable and sustained remission of an anaplastic thyroid carcinoma patient to the combined treatment of multimodal radiotherapy, anlotinib and toripalimab

## TL;DR

A patient with aggressive thyroid cancer achieved long-term remission using a combination of radiotherapy, anlotinib, and toripalimab.

## Contribution

This case report presents a successful multimodal treatment approach for anaplastic thyroid carcinoma.

## Key findings

- The patient experienced significant tumor shrinkage after multimodal radiotherapy.
- Combination therapy with anlotinib and toripalimab led to long-term disease control.
- This treatment approach offers a promising new option for ATC patients.

## Abstract

Anaplastic thyroid carcinoma (ATC) is an infrequent malignant tumor that has a high death rate and a poor prognosis. The therapeutic methods for ATC include traditional surgery, chemoradiotherapy and targeted therapy. However, the effect of ATC treatment is not ideal. We report a patient with ATC who developed rapid local recurrence and multiple systemic metastases after radical thyroidectomy. After multimodal radiotherapy, antiangiogenic therapy and immunotherapy, the patient’s tumors shrunk significantly and achieved long-term control. The therapeutic effect was remarkable. These findings provide a viable new treatment choice for ATC patients in the future.